Insights

Virtus Health (ASX:VRT) share price remains halted after profit boost and acquisition

The ASX-healthcare share delivered its full-year results and announced a major acquisition this morning.
The post Virtus Health (ASX:VRT) share price remains halted after profit boost and acquisition appeared first on The Motley Fool Australia. –

The Virtus Health Ltd (ASX: VRT) share price remains frozen at the time of writing at the company’s request. Shares will resume trading tomorrow.

The ASX healthcare share’s offerings include fertility, medical day procedure, and medical diagnostic services.

Virtus Health’s share price was put into a trading halt pending the company’s acquisition announcement, which it released today. It also released its full-year results for the 2021 financial year.

First, a look at the acquisition.

The Virtus Health share price frozen on acquisition announcement

Virtus reported that it has entered into a share sale agreement to acquire Adora Fertility and 3 Day Hospitals from Healius Ltd (ASX: HLS) for $45 million.

The company will fund the acquisition with an underwritten $35 million institutional placement along with existing cash reserves. It will issue new shares at a fixed price of $6.80 per share. The Virtus share price closed at $7.19 on Friday.

Management expects the acquisition to be completed in the second quarter of the 2022 financial year. That is, subject to the customary conditions.

Commenting on the deal, Virtus CEO Kate Munnings said:

This acquisition supports our ambition to increase consumer choice by offering diverse models of care across new locations. It also takes our day hospital network to ten facilities and represents our entry into WA.

What did Virtus report for FY21?

Revenue of $324.6 million, up from $258.9 million in FY20
Reported earnings before interest, tax, depreciation and amortisation (EBITDA) of $93.4 million, up from $46.2 million in FY20
Reported net profit after taxes (NPAT) attributable to shareholders of $43.1 million, up from $500,000 in FY20
Declared a final dividend of 12 cents per share, fully franked

What happened during the reporting period for Virtus?

The company’s Australian segment saw revenue increase 24.4% compared to the prior corresponding period (pcp), while EBITDA increased by 30.1%.

Virtus said it was able to make the most of the “buoyancy in market activity” during the financial year. It did this via detailed planning for the restart of elective surgery, with doctors and staff available for the reopening.

The company said a greater focus on home and family during the COVID-19 pandemic saw more new patients commencing with its assisted reproductive services (ARS).

Revenue in the company’s day hospitals increased by 41.4%. That was partly driven by the increase in demand for IVF procedures. However, demand for non-IVF procedures grew to account for 45% of total day hospital revenue.

What did management say?

Commenting on the results, Munnings said:

It was a very strong performance across all our services globally, in the face of the ongoing COVID-19 impacts of border closures, lockdowns and heightened infection control requirements.

The challenges of providing essential services in the current conditions should not be underestimated and the strong results are a testament to all Virtus Health staff and specialists who have worked extremely hard throughout the year.

She added, “What was also pleasing was the growth in revenue across our day hospitals which was driven by improved utilisation, including an increase in non-IVF revenue.”

What’s next for Virtus shares?

Looking ahead, Munnings said:

Our FY21 results have positioned Virtus to invest in future growth including by developing new clinics in Nepean, Copenhagen & Brisbane; enhancing our capability in Fertility Diagnostics & Reproductive Genetics and by developing the Precision Fertility Digital Platform to enable innovation and efficiency.

While its ARS services are currently continuing to operate across all states, the company cautioned that the Delta variant poses a risk that some treatments may need to be deferred.

The Virtus Health share price is up 111% over the past 12 months.

The post Virtus Health (ASX:VRT) share price remains halted after profit boost and acquisition appeared first on The Motley Fool Australia.

Should you invest $1,000 in Virtus Health right now?

Before you consider Virtus Health, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Virtus Health wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why the Kalium Lakes (ASX:KLL) share price is rocketing 14% today
Why Ampol, NIB, Redbubble, & Sonic shares are dropping

Z Energy (ASX:ZEL) share price surges 15% on acquisition news
Here’s how the Kogan (ASX:KGN) share price responded last reporting season
Revealed: The biggest shocker from results season

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Virtus Health Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!